Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results

European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for TransConTM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD)

Submitted regulatory filings to enable initiation of European and Canadian sites for phase 3 PaTHway Trial for TransCon PTH

In collaboration with VISEN Pharmaceuticals, filed an Investigational New Drug Application (IND) to initiate the phase 2 ACcomplisH China Trial of TransCon CNP

On track for remaining 2020 corporate milestone of filing an IND or similar for TransCon TLR7/8 Agonist by year-end

Conference call today at 4:30 p.m. Eastern Time

COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced financial results for the quarter ended September 30, 2020.

“As Ascendis progresses toward closing out 2020, I am proud that we are on track or ahead of schedule for all 2020 corporate goals and to achieve Vision 3x3, moving us one step closer to becoming a fully integrated, global biopharmaceutical company,” said Jan Mikkelsen, President and CEO. “As a company, we are driven by our core values to achieve our long-term strategic Vision 3x3, using the power of the TransCon technology. We push ourselves to continually deliver not only in endocrinology but also in oncology and to bring these products to patients as efficiently and safely as possible.”

Corporate Highlights & Progress

  • TransCon hGH (lonapegsomatropin)
    ○  Submitted MAA to the EMA, which has now validated the application.
    ○  Filed a Clinical Trial Notification with the Pharmaceuticals and Medical Devices Agency in Japan to initiate the company’s phase 3 riGHt Trial of lonapegsomatropin for the treatment of pediatric GHD.
    ○  Announced the U.S. Food and Drug Administration (FDA) accepted the company’s Biologics License Application and set a PDUFA date for June 25, 2021.
  • TransCon PTH
    ○  Submitted regulatory filings to enable initiation of European and Canadian sites for phase 3 PaTHway Trial.
    ○  Received orphan designation by the European Commission (EC) for the treatment of hypoparathyroidism (HP).
    ○  Submitted an amendment to its IND with FDA for the PaTHway phase 3 clinical trial evaluating the safety, tolerability and efficacy of TransCon PTH in adults with HP.
    ○  Announced preliminary six-month results from the open-label extension portion of PaTH Forward, a global phase 2 trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with HP. The preliminary results support potential use of TransCon PTH as a hormone replacement therapy for HP and demonstrated normalization of quality of life.
  • TransCon CNP
    ○  In collaboration with VISEN Pharmaceuticals, filed an IND application to initiate the phase 2 ACcomplisH China Trial.
    ○  Received orphan designation by the EC.
  • Oncology
    ○  On track for filing IND or similar for TransCon TLR7/8 Agonist by year-end. TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod. Administered as an intratumoral injection, TransCon TLR7/8 Agonist is designed to provide sustained release of unmodified resiquimod directly to the tumor.
  • Announced Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases. Dr. Bach has 30 years of experience in clinical research and development.
  • Ended the third quarter 2020 with cash, cash equivalents and marketable securities totaling €957.5 million.

Third Quarter 2020 Financial Results

For the third quarter, Ascendis Pharma reported a net loss of €121.7 million, or €2.31 per share (basic and diluted) compared to a net loss of €25.1 million, or €0.53 per share (basic and diluted) for the same period in 2019.

Revenue for the third quarter was €2.8 million compared to €2.2 million in the same quarter of 2019. The increase was due to a higher sale of clinical supply and services to VISEN, partly offset by a lower amount of license revenue being recognized.

Research and development (R&D) costs for the third quarter were €64.1 million compared to €46.3 million during the same period in 2019. Higher R&D costs in 2020 reflect an increase in personnel-related costs, expansion of R&D facilities and the continued progress in development of the company’s product candidates.

Selling, general and administrative (SG&A) expenses for the third quarter were €17.5 million compared to €10.0 million during the same period in 2019. The increase is primarily due to additional personnel-related costs, higher IT and other infrastructure costs and continued build of the company’s commercial capabilities.

As of September 30, 2020, Ascendis Pharma had cash, cash equivalents and marketable securities totaling €957.5 million compared to €471.6 million as of June 30, 2020. As of September 30, 2020, Ascendis Pharma had 53,416,091 ordinary shares outstanding.

Conference Call and Webcast information

Ascendis Pharma will host a conference call and webcast today at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2020 financial results. Details include:

DateNovember 11, 2020
Time4:30 p.m. ET
Dial In (U.S.)844-290-3904
Dial In (International)574-990-1036
Access Code8955314

A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma’s Pipeline

Ascendis Pharma currently has three product candidates in clinical development in rare endocrine diseases:

  • TransCon hGH (lonapegsomatropin), an investigational long-acting prodrug of somatropin (human growth hormone or hGH) that releases somatropin with the identical amino acid sequence and size as daily growth hormone, is designed as a once-weekly treatment for GHD and is currently under regulatory review by the U.S. Food and Drug Administration and the European Medicines Agency.
  • TransCon PTH, an investigational long-acting prodrug of parathyroid hormone (PTH) in phase 3 development as a once-daily replacement therapy for hypoparathyroidism (HP) designed to replace PTH at physiologic levels for 24 hours every day, and address both short-term symptoms and long-term complications of the disease.
  • TransCon CNP, an investigational long-acting prodrug of C-type natriuretic peptide (CNP) in phase 2 development as a therapy for children with achondroplasia (ACH), the most common form of dwarfism, for which there is no FDA-approved treatment. TransCon CNP is designed to provide continuous exposure of CNP at safe, therapeutic levels via a single, weekly subcutaneous dose.

Additionally, the company has established oncology as its second therapeutic area of focus and plans to submit an IND or similar by year-end for TransCon TLR7/8 Agonist, the company’s first oncology product candidate.

About Ascendis Pharma A/S 

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ 2020 corporate goals and Vision 3x3, (ii) Ascendis’ PDUFA date for its Biologics License Application for lonapegsomatropin, (iii) Ascendis’ planned IND filing for TransCon TLR7/8 Agonist by year-end, (iv) Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharma company, (v) Ascendis’ product pipeline and expansion into additional therapeutic areas and (vi) Ascendis’ expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, lonapegsomatropin, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, lonapegsomatropin, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its oncology programs, lonapegsomatropin, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to obtain additional funding, if needed, to support its business activities and the effects on its business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on July 9, 2020 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © November 2020 Ascendis Pharma A/S.

FINANCIAL TABLES FOLLOW

 
Ascendis Pharma A/S 
Consolidated Statements of Profit or Loss and Other Comprehensive Income / (loss)
(In EUR'000s, except share and per share data) 
        
 Three Months Ended September 30, Nine Months Ended September 30,
        
 2020 2019 2020 2019
        
Revenue2,757  2,243  6,418  10,868 
Research and development costs(64,059) (46,258) (185,152) (141,343)
Selling, general and administrative expenses(17,523) (10,000) (56,243) (31,396)
Operating profit / (loss)(78,825) (54,015) (234,977) (161,871)
        
Share of profit / (loss) of associate(3,101) (1,338) (6,501) (5,452)
Finance income136  30,547  1,677  30,285 
Finance expenses(39,970) (368) (40,391) (812)
Profit / (loss) before tax(121,760) (25,174) (280,192) (137,850)
        
Tax on profit / (loss) for the period19  61  202  196 
Net profit / (loss) for the period(121,741) (25,113) (279,990) (137,654)
        
Attributable to owners of the Company(121,741) (25,113) (279,990) (137,654)
        
Basic and diluted earnings / (loss) per share (2.31)  (0.53)  (5.64)  (2.99)
        
Number of shares used for calculation (basic and diluted)52,715,204  47,590,837  49,647,471  46,066,493 
        
        
        
Net profit / (loss) for the period(121,741) (25,113) (279,990) (137,654)
Other comprehensive income / (loss)       
Items that may be reclassified subsequently to profit or loss:       
Exchange differences on translating foreign operations(75) 37  (136) 2 
Other comprehensive income / (loss) for the period, net of tax(75) 37  (136) 2 
        
Total comprehensive income / (loss) for the period, net of tax(121,816) (25,076) (280,126) (137,652)
        
Attributable to owners of the Company(121,816) (25,076) (280,126) (137,652)
        


 
Ascendis Pharma A/S
Consolidated Statements of Financial Position
(In EUR'000s)
      
 September 30,
 December 31,
 2020
 2019
Assets     
Non-current assets     
Intangible assets4,653  3,495 
Property, plant and equipment47,325  45,069 
Investment in associate11,574  15,538 
Deposits1,243  1,463 
Marketable securities27,728  - 
 92,523  65,565 
      
Current assets     
Trade receivables2,722  804 
Other receivables4,511  3,136 
Prepayments15,266  7,648 
Income taxes receivable1,305  1,473 
Marketable securities166,343  - 
Cash and cash equivalents763,454  598,106 
 953,601  611,167 
      
Total assets1,046,124  676,732 
      
Equity and liabilities     
Equity     
Share capital7,172  6,443 
Distributable equity944,413  590,671 
Total equity951,585  597,114 
      
Non-current liabilities     
Lease liabilities26,952  30,720 
Other payables3,160  908 
 30,112  31,628 
      
Current liabilities     
Lease liabilities6,328  5,899 
Contract liabilities223  858 
Trade payables and accrued expenses38,108  27,765 
Other payables19,549  13,349 
Income taxes payable219  119 
 64,427  47,990 
      
Total liabilities94,539  79,618 
      
Total equity and liabilities1,046,124  676,732 
      


Investor contacts:Media contact:
Tim LeeRon Rogers
Ascendis PharmaAscendis Pharma
(650) 374-6343(650) 507-5208
tle@ascendispharma.comrrs@ascendispharma.com
  
Patti Bank 
Westwicke Partners 
(415) 513-1284 
patti.bank@westwicke.com 
ir@ascendispharma.com 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.